Hanchen Zhou | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Mr. Hanchen Zhou | Medicine and Health Sciences | Best Researcher Award

Beijing Stomatological Hospital Affiliated to Capital Medical University | China

Hanchen Zhou, a graduate student at Beijing Stomatological Hospital, Capital Medical University, is an emerging researcher specializing in Oral and Maxillofacial-Head and Neck Oncology, with a primary focus on oral squamous cell carcinoma. He has already distinguished himself by publishing four SCI-indexed research papers that contribute valuable insights into the molecular mechanisms, clinical behavior, and potential treatment strategies for this aggressive malignancy. These publications, cited internationally, reflect his growing influence in oncology research and his ability to translate clinical challenges into innovative scientific solutions. Zhou is actively engaged in funded research projects, including the Innovation Foundation and the Clinical Research Incubation Project of Beijing Stomatological Hospital, demonstrating his capacity to design and execute impactful investigations. A member of the Chinese Stomatological Association, he actively participates in academic collaboration and professional development, strengthening his role within the wider scientific community. Despite being in the early stages of his career, Zhou has already showcased a strong commitment to advancing cancer research, particularly in bridging experimental findings with clinical applications. His work not only enhances the understanding of oral squamous cell carcinoma but also paves the way for improved diagnostic and therapeutic approaches. By integrating scientific rigor with a clear vision for innovation, he exemplifies the qualities of a promising researcher poised for long-term impact.

Profile: Scopus | ResearchGate

Featured Publications

  • Yu, H., Li, B., Huang, Y., & Zhang, X. (2025). Prognosis of second primary oral squamous cell carcinoma after hematologic malignancy: A retrospective cohort analysis. Frontiers in Oncology, 15, Article 1667226. https://doi.org/10.3389/fonc.2025.1667226

  • Zhou, H., Luo, C., Xu, Q., & Wang, C. (2025). Machine learning approach to predict surgical site infection in head and neck squamous cell carcinoma patients after free flap reconstruction. Journal of Cranio-Maxillofacial Surgery. Advance online publication. https://doi.org/10.1016/j.jcms.2025.09.010

  • Cheng, A., Wei, K., Xu, Q., & Wang, C. (2025). The comparison of the prognostic value of different inflammation-related indicators in patients with oral squamous cell carcinoma. Frontiers in Genetics, 16, Article 1652603. https://doi.org/10.3389/fgene.2025.1652603

  • Li, B., Zhao, Z., Huang, Y., & Zhou, H. (2025). The application of adjuvant radiotherapy in pN1 OSCC patients without adverse pathologic features. Oral Diseases, 31(1), e15336. https://doi.org/10.1111/odi.15336

Long Chang | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Long Chang | Medicine and Health Sciences | Best Researcher Award

Peking Union Medical College Hospital | China

Dr. Long Chang is an accomplished physician and clinical researcher whose career demonstrates excellence in patient care and significant contributions to hematology. He currently serves as an Attending Physician at the Department of Hematology, Peking Union Medical College Hospital, Beijing, China, building upon his medical training at Peking Union Medical College, Tsinghua University. His research focuses on rare hematologic disorders, particularly myeloproliferative neoplasms and histiocytic diseases, with emphasis on improving diagnostic precision, expanding therapeutic strategies, and enhancing patient outcomes. According to Scopus (Author ID: 57225110413), Dr. Long Chang has authored 39 publications, which have collectively received 165 citations across 152 documents, reflecting the impact of his work, and holds an h-index of 6. He has published influential studies in leading journals including Leukemia, EClinicalMedicine, Oncologist, and Orphanet Journal of Rare Diseases. His work has advanced treatment options for Rosai-Dorfman disease and Langerhans cell histiocytosis while also providing novel insights into gamma heavy chain disease. Notably, his clinical trials have introduced promising approaches such as low-dose cytarabine and novel immunomodulatory therapies, offering alternatives for conditions with limited treatments. Beyond publications, Dr. Long Chang demonstrates commitment to translational medicine by bridging molecular research with patient-centered care. Recognized by peers for his rigor, innovation, and leadership, he has progressed from Resident and Chief Resident to Attending Physician, reflecting both clinical expertise and academic excellence. With impactful contributions influencing practice worldwide, Dr. Long Chang exemplifies the qualities of a dedicated physician-scientist whose work continues to advance the frontiers of hematology.

Profile: Scopus

Featured Publications

  • Chang, L., Zhou, D. B., & Cao, X. X. (2023). Gamma heavy chain disease: A retrospective analysis of 6 cases. Orphanet Journal of Rare Diseases, 18(1), 77.

  • Chang, L., Qiao, B., Cai, H., et al. (2023). Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia, 37(11), 2297–2300.

  • Chang, L., Lang, M., Lin, H., et al. (2024). Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia, 38(4), 803–809.

  • Chang, L., Lang, M., Liu, T., et al. (2024). Lenalidomide and dexamethasone for Rosai-Dorfman disease: A single arm, single center, prospective phase 2 study. EClinicalMedicine, 73, 102685.

  • Chang, L., Cai, H. C., Lang, M., et al. (2024). Liver involvement with Langerhans cell histiocytosis in adults. The Oncologist. Advance online publication.